Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 1006 Uterine Cervical Neoplasms 420 Endometrial Neoplasms 350 Carcinoma, Non-Small-Cell Lung 292 Breast Neoplasms 292 Neoplasms 238 Colorectal Neoplasms 233 Fallopian Tube Neoplasms 211 Stomach Neoplasms 192 Pancreatic Neoplasms 184 Melanoma 157 Prostatic Neoplasms 152 Triple Negative Breast Neoplasms 148 Carcinoma, Ovarian Epithelial 147 Lung Neoplasms 136 Neoplasm Metastasis 133 Squamous Cell Carcinoma of Head and Neck 131 Carcinoma, Renal Cell 130 Head and Neck Neoplasms 122 Esophageal Neoplasms 121 Urinary Bladder Neoplasms 112 Small Cell Lung Carcinoma 90 Sarcoma 80 Carcinoma, Hepatocellular 76 Recurrence 70 Carcinoma, Transitional Cell 70 Uterine Cervical Dysplasia 66 Papillomavirus Infections 66 Colonic Neoplasms 59 Cholangiocarcinoma 59

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Cancer Metastatic × Gynecologic × Clear all

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡